Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2021-09-30 Interim / Quarterly Rep…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Sprawozdanie Zarządu
Interim / Quarterly Report Classification · 100% confidence The document is a 'Raport półroczny' (Semi-annual report) for Celon Pharma S.A. for the first half of 2021. It contains detailed financial statements, management commentary on financial results, information about the company's business activities, R&D projects, and board composition. Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2021
2021-09-30 Polish
Rejestracja akcji serii D w KDPW - Content (PL)
Regulatory Filings Classification · 99% confidence The document text is very short (483 characters) and announces that the Management Board of Celon Pharma S.A. has received notice regarding the registration of 6,000,000 Series D shares by the National Securities Depository (KDPW) and that these shares will be admitted to trading on the Warsaw Stock Exchange (GPW) starting September 22, 2021. This is a specific regulatory announcement concerning the listing/admission of new shares to trading. This fits best under 'Share Issue/Capital Change' (SHA) as it confirms the final step for shares to enter the market, or potentially 'Regulatory Filings' (RNS) if SHA is too specific for a mere admission notice. Given the context of capital structure changes being finalized for trading, SHA is the most precise fit among the defined categories, as it relates directly to the shares being introduced to the market.
2021-09-22 Polish
Uzupełnienie raportu bieżącego nr 35/2021 w sprawie podsumowania subskrypcji akcji zwykłych na okaziciela serii D Celon Pharma S.A. - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a continuation ('uzupełnienie') of a previous current report (raport bieżący) detailing the costs associated with a subscription of new shares (Akcje serii D). It specifically quantifies the total issuance costs (kosztów emisji) and the average cost per security. This content directly relates to capital structure changes, fundraising activities, and the associated expenses, which aligns best with the 'Capital/Financing Update' category. Although it is a follow-up report, the core subject matter is financing costs, making CAP more specific than a general RPA or RNS.
2021-09-20 Polish
Dopuszczenie i wprowadzenie akcji zwykłych na okaziciela serii D Spółki do obrotu giełdowego - Content (PL)
Report Publication Announcement Classification · 99% confidence The document is a formal announcement from the Management Board of Celon Pharma S.A. regarding a resolution passed by the Warsaw Stock Exchange (GPW) to admit and introduce 6,000,000 Series D ordinary bearer shares into stock exchange trading, effective September 22, 2021. This concerns the listing and introduction of new shares to the market, which falls under capital structure changes or financing activities. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate fit as it relates directly to the introduction of new shares into trading. It is not a general regulatory filing (RNS) because it is specific to a capital event.
2021-09-16 Polish
Warunkowa rejestracja akcji serii D Spółki w KDPW - Content (PL)
Share Issue/Capital Change Classification · 95% confidence The document text is very short (757 characters) and announces an action taken by the Management Board regarding the conditional registration of 6,000,000 Series D shares by the National Securities Depository (KDPW). The core subject is the registration/introduction of new shares into the securities deposit, contingent on their admission to trading on a regulated market. This directly relates to a change in the company's capital structure or the issuance of new shares. The most fitting category is 'Share Issue/Capital Change' (SHA). It is not a general regulatory filing (RNS) because it is specific to a capital event, nor is it a financing update (CAP) which usually implies fundraising activities like debt or equity issuance for cash.
2021-09-16 Polish
Otrzymanie zawiadomienia o zmianie udziału w ogólnej liczbie głosów w Spółce - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document is a formal notification from the Management Board of Celon Pharma S.A. regarding a change in the shareholding percentage of Mr. Maciej Wieczorek, citing specific articles of the Polish Public Offering Act ('Ustawa o ofercie publicznej'). The content details the number of shares and voting rights held before and after a capital increase event (registration of Series D shares on September 9, 2021). This structure—reporting changes in significant share ownership thresholds by an insider or major shareholder—directly corresponds to the definition of a Major Shareholding Notification. In the provided schema, this aligns best with 'Major Shareholding Notification' (MRQ).
2021-09-10 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.